# The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer

> **NCT06269445** · PHASE4 · UNKNOWN · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Icaritin Combined With Bevacizumab and FOLFIRI

## Key facts

- **NCT ID:** NCT06269445
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269445, "The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06269445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*